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Proteins expressed by recombination activating genes 1 and 2 (RAG1/2) are essential in
the process of V(D)J recombination that leads to generation of the T and B cell repertoires.
Clinical and immunological phenotypes of patients with RAG deficiencies correlate
well to the degree of impaired RAG activity and this has been expanding to variants
of combined immunodeficiency (CID) or even milder antibody deficiency syndromes.
Pathogenic variants that severely impair recombinase activity of RAG1/2 determine a
severe combined immunodeficiency (SCID) phenotype, whereas hypomorphic variants
result in leaky (partial) SCID and other immunodeficiencies. We report a patient with
novel pathogenic compound heterozygous RAG2 variants that result in a CID phenotype
with two distinctive characteristics: late-onset progressive hypogammaglobulinemia and
highly elevated B cell count. In addition, the patient had early onset of infections, T cell
lymphopenia and expansion of lymphocytes after exposure to herpes family viruses. This
case highlights the importance of considering pathogenic RAG variants among patients
with preserved B cell count and CID phenotype.
Keywords: RAG deficiency, RAG2, combined immunodeficiency, primary immunodeficiency, hypomorphic variant,
compound heterozygous variant
INTRODUCTION
RAG1 and RAG2 proteins combine to form a heterotetrameric complex which acts as an
endonuclease. The RAG recombinase complex performs the essential first step in recombining
variable (V), diversity (D), and joining (J) segments of antigen receptor genes that generate the
diversity of T and B cell receptors (TCR, BCR) (1). TCR and BCR are important not only for
the function of antigen recognition by T and B cells, but also for their development and survival.
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TABLE 1 | Lymphocytes subsets profile (count/microliter) and lymphocyte proliferation to mitogens and antigens over 4 years [stimulation index (SI*)].
Lymphocyte subset absolute (count/microliter) Age (years) Normal value
(10–15 years)
10.5 12 12.6 13.9 14.3
Lymphocytes 1,110 (L) 1,640 2,140 3,650 2,880 >1,300
CD3T cells 617 (L) 509 (L) 706 (L) 1,619 1,042 >1,000
CD4T cells 285 (L) 285 (L) 302 (L) 680 367 (L) >530
CD8T cells 342 (L) 224 (L) 360 (L) 980 662 >350
CD19 B cells 504 1,246 1,681 1,339 >110
CD56 NK cells 380 156 201 468 >70
CD4+CD45RA+ T cells 53 (10.4%) (L) >37%
Lymphocyte proliferation to
mitogens and antigens (SI)*
PHA 15.93 33.3 >18
PWM 35.1 >8
Anti-CD3 63 >15
TT 0.8 (L) >3.6
CMV 0.7 (L) >3.6
candida 1.6 (L) >3.3
L, low; NK, natural killer; PHA, phytohemagglutinin; PWM, pokeweed mitogen; CD, complementarity-determining region; TT, tetanus toxoid; CMV, cytomegalovirus.
*The stimulation index is the ratio of counts per minute of stimulated vs. unstimulated (background) cells.
Variants in RAG1 and RAG2 are associated with many different
immunodeficiencies including T−B−NK+ SCID, Omenn
syndrome (OS), leaky SCID (LS) with γδ T cell expansion,
and combined immunodeficiency with granulomas and/or
autoimmunity (CID-G/AI) (2–5). Increasing access to genetic
studies of immunodeficient patients is expanding the spectrum
of phenotypes attributed to RAG deficiency. More recently,
hypomorphic RAG variants were identified in patients with
CD4+ T cell lymphopenia, and phenotypes resembling
common variable immunodeficiency (CVID) and specific
anti-polysaccharide antibody deficiency affecting all ages (6–10).
In this report, we present a patient with CID associated with
novel compound heterozygous RAG2 variants. The clinical
and immune phenotype includes early onset of infections, T
cell lymphopenia, normal B cell count, late onset progressive
hypogammaglobulinemia, and evolving expansion of T and B
lymphocytes with exposure to herpes family viruses.
Case Presentation
A 14-year-old female with chronic rhinosinusitis and lung
disease with bronchiectasis was referred for immunologic
investigation in São Paulo, Brazil. She had a history of chronic
cough with recurrent wheezing since birth with prolonged
use of antimicrobials for lower and upper respiratory tract
infections, oral candidiasis and stomatitis. She had one episode
of pneumonia and she was never hospitalized. She is an offspring
of non-consanguineous parents. One of her sisters died with
leukemia at the age of 9 months, and her mother experienced
recurrent pneumonias and otitis media in childhood.
At 8.5 years of age, pulmonary symptoms worsened,
bronchiectasis was detected on computed tomography and
pulmonary function assessment showed mild obstructive lung
disease. Cystic fibrosis and ciliary dyskinesia were excluded. She
was treated with inhaled corticosteroids, azithromycin and chest
physical therapy for 2 years with poor clinical response.
Immune evaluation was performed at several time points in
the period of 8.5–14.3 years of age (Tables 1, 2). Total lymphocyte
count was grossly preserved. Immunoglobulin (Ig) levels were
variable with low IgA, low to normal IgG and low to high
IgM initially. By 10 years of age, laboratory evaluation showed
low levels of all Ig isotypes and low CD4+ and CD8+ T cells
with low fraction of CD45RA+ naïve cells and skewing to
activated memory T cell phenotype. Lymphocyte proliferation
was normal with mitogens but impaired with antigen stimulation
(Table 1). As Ig levels decreased, treatment with intravenous
Ig (IVIG) was initiated at 11 years of age (Table 2). There
was no evidence of protein loss. The B cell developmental
subsets were significantly skewed with a marked decline in
the switched memory B cell compartment (Table 3). B cell
dysfunction is also reflected by decreased total IgG, IgM, and
IgA levels with increased age (Table 2). Anti-thyroglobulin and
anti-thyroperoxidase antibodies were persistently positive with
normal thyroid function.
Regarding infectious complications, symptoms of respiratory
infections improved on intravenous immunoglobulin G (IVIG)
replacement therapy. However, recurrent candidiasis continued
to occur as well as episodes of oral ulcers. At 13 years of age,
she was hospitalized with bilateral pneumonia and stomatitis
with positive polymerase chain reaction (PCR) for herpes simplex
virus (HSV) on oral lesion biopsy. She responded well to
intravenous antibiotics and acyclovir. Persistently, Epstein-Barr
virus (EBV) and intermittently, cytomegalovirus (CMV) viral
loads were detected without obvious clinical manifestations of
lymphoproliferation or acute viral distress since 11.8 years for
EBV and 13.4 years of age for CMV (Figure 1). A progressive
increase in CD8+ T cells, B cells (CD19+) and natural killer
(NK) cells (CD16+CD56+) was noticed in the same period
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TABLE 2 | Immunoglobulin (Ig) levels and anti-cytokine antibodies before and after
IgG replacement therapy, which was begun at 11 years of age.
Ig class Age (years)
8.5 9.6 10.8 11 14.1
IgG
(mg/dL)
1,055
(633–1,280)
713 (L)
(1,000–1,516)
537 (L)
(970–1,710)
454 (L)
(970–1,710)
1,118*
(639–1,349)
IgM
(mg/dL)
225.5
(59–151)
66
(59–151)
32.6 (L)
(53–145)
25.9 (L)
(53–145)
16.4
(15–188)
IgA
(mg/dL)
13.8 (L)
(33–220)
<50 (L)
(45–234)
<5 (L)
(45–234)
<0.1 (L)
(69–382)
0.1 (L)
(47–259)
IgE
(IU/mL)
<4
(<90)
5
(<90)
<0.1
(<200)
<0.1
(<200)
<0.1
(<200)
Anti-cytokine antibodies Anti-IFN-α
Anti-IFN-ω
Anti-IL-12
Present (H)
Absent
Absent
Normal range of Ig class concentrations in parentheses.
L, low; H, high; IFN, interferon; IL, interleukin.
IFN-α, interferon alpha; IFN-ω, interferon omega; IL-12, interleukin 12
*On IvIg.
TABLE 3 | B cells subset percentages at 13.9 and 14.3 years of age.
B cell subsets 13.9 (years) 14.3 (years)
CD19 (% of live lymphocytes) 78.4% (H) (14.9%)* 56.5% (H) (9.9%)*
Naïve (% of CD19+) 70.4% (57.4%) 61.9% (59.9%)
Memory (% of CD19+) 12.9% (L) (33.5%) 19.6% (31.7%)
IgD only (% of CD27+) 20.6% (24.9%) –
IgM only (% of CD27+) 13.3% (13.3%) –
IgD IgM positive (marginal zone)
(% of CD27+)
59.6% (30.8%) –
IgD IgM negative (switched)
(% of CD27+)
6.5% (L) (31.0%) –
Double negative (% of CD19+) 14.9% (8.3%) 15.7% (7.4)
*Values in parentheses belong to a healthy control donor that were measured in the same
experiment as that of the patient. H, high; L, low.
(Figure 1). Testing at 14 years of age revealed the presence of
antibodies targeting interferon-alpha (anti-IFN-α) (Figure 1).
Genetic studies using targeted sequencing of 16 SCID
genes identified a heterozygous compound variant in RAG2
(c.509A > G: p.E170G and c.829insT, p.Y277fs) in the coding
regions. Both components of the compound variant were novel.
The heterozygous variant was confirmed by Sanger sequencing.
The c.509A>G, p.E170G variant was present in the mother. The
father was unavailable for study.
Based on prediction analysis and structural modeling, it is
expected that the mutated RAG2 allele with Y277fs will not
contribute any recombinase activity as truncation of RAG2
further than amino acid 350 leads to a non-functioning protein
that is unlikely to form any complex with RAG1 (11).Mutation in
the RAG2 E170 is likely important in RAG1/2 dimerization as it
contacts an arginine residue in RAG1 (R561). Mutation of RAG1
R561 to histidine has been previously reported inOmenn patients
and shown to have reduced DNA binding and cleavage activity,
but retains some activity in vitro (12). Therefore, we predicted
that RAG2 E170G will perform all of the recombinase activity in
the patient.
The relative recombinase activity of the RAG2 variants in
vitro individually and in a bi-cistronic system was tested using
methods previously reported (13). The relative recombinase
activity level of the protein expressed by RAG2 p.E170G variant
was 14.2% ± 1.6 standard error of mean (SEM) whereas the
p.Y227fs variant had zero activity and their combined activity
was 16.2% ± 2.5 SEM in an in vitro system (Figure 2). Thus,
the RAG2 E170G variant solely contributed to the partial
recombinase activity of the patient.
Although considered, the family elected to wait with
hematopoietic stem cell transplantation. Regarding donor
selection, there is no matched sibling available and we await
results of human leukocyte antigen testing to search for a
matched unrelated donor.
METHODS
Targeted genes sequencing was performed using genomic
DNA extracted from peripheral blood with Qiagen columns
(QIAamp DNA Mini Kit; Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. PCR was
carried out by a set of primers designed using www.
bioinformatics.nl/primer3plus for all genes (IL2RG:NM_000206,
ADA:NM_000022, JAK3:NM_000215, ORAI1:NM_032790,
RAG1:NM_000448, RAG2:NM_001243785, GATA2:NM_0
01145662, CD247:NM_000734, CD3D:NM_000732,
CD3E:NM_000733, CD3G:NM_000073, LCK:NM_005356,
NHEJ1:NM_024782, IL7R:NM_002185, LIG4:NM_206937,
and PNP:NM_000270). The genes were sequenced using
targeted sequencing performed with Nextera R©XT DNA Library
Preparation Kit (Illumina, San Diego, CA, USA) according
to the manufacturer’s instructions. Variants were identified
using Platypus software (Welcome Centre for Human Genetics,
Oxford, UK) and annotated using Annovar, an open source
software tool. In order to predict the impact of these variants
on the protein function, we employed in silico prediction tools:
PhyloP, SIFT, PolyPhen-2, LRT and VariantTaster. The variants
considered important were Sanger sequenced. PCR products
were directly sequenced with BigDye Terminators (version
3.1) and analyzed on a Genetic Analyzer (Applied Biosystems.
Foster City, CA, USA). B and T cells subset populations were
determined by flow cytometry and analyzed using FlowJo
software (Treestar, Ashland, OR, USA). Anti-cytokine antibodies
were measured by enzyme-linked immunosorbent assay as
previously described (4). Recombinase activity level was
determined using bi-cistronic in vitro method performed in
triplicate as described by Thwaites et al. (13).
DISCUSSION
Impaired RAG function is associated with different clinical and
immunological phenotypes and usually presents with variable
degrees of B and T cell lymphopenia and antibody deficiency.
The reported RAG deficient patient has a CID phenotype
with two distinctive characteristics: late-onset progressive
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FIGURE 1 | Lymphocyte subset counts and viral copy numbers over 4 years. An increase of T and B cell counts has been observed in the last 2.5 years coincidently
with cytomegalovirus (CMV) and Epstein-Barr virus (EBV) viremia, and herpes simplex virus (HSV) stomatitis as shown by polymerase chain reaction.
Anti-interferon-alpha antibodies (anti-IFN-α) were present at 14 years of age.
FIGURE 2 | Recombination activity of two heterozygous RAG2 pathogenic
variants (E170G, Y227fs) alone and in combination relative to the wild type
allele (wtRAG2). -RAG2 is a negative control.
hypogammaglobulinemia and normal B cell count. The patient
does not meet the criteria for LS or OS as mitogen proliferation
are preserved, and has higher relative RAG activity [16% in
combined variants (Figure 2)] compared to LS/OS patients. This
is consistent with most CID patients having RAG activity ranging
from 10 to 60% of wild type RAG activity (12, 14).
Late onset progressive hypogammaglobulinemia has been
previously identified in patients with pathogenic RAG variants.
Buchbinder et al. (8) reported two patients who not only had
decreasing Ig levels but also a later onset of clinical symptoms,
both of which contributed to the delay in correct diagnosis.
Patients with late onset CID (LOCID) may be misdiagnosed
with CVID due to similarities in clinical and immunologic
characteristics (8). Nevertheless, patients with LOCID usually
present with lower T cell counts and a marked decrease in CD4+
T cells in particular naïve T cells, compared to CVID patients
(15). The findings that led to the hypothesis of CID in our patient
and motivated the search for the underlying genetic defect were
early onset of recurrent bacterial, viral and fungal infections
associated with marked reduction of CD4+ and CD45RA naïve
T cells with skewing to activated memory phenotype.
Another interesting immunologic finding in this patient is
the presence of a normal B cell count. Due to the importance
of the recombinase activity of RAG1/2 for B cell development
and repertoire diversity, RAG variants are usually associated with
marked B cell lymphopenia. However, normal B cell count has
been found in other young patients with RAG variants, including
patients with CID, ages 2.5 months and 2 years, respectively (16,
17). In both cases, the patients had active herpes virus infections
(CMV and varicella specifically). The oldest RAG deficient
patient reported with normal B cell count has been recently
published by our group [Patient #12 in Lawless et al. (10)]. This
64 year-old female patient with RAG1 compound heterozygous
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variants (M435V andM1006V) and relative recombinase activity
of 28%, had a normal B cell count of 216 (cells/µl) (10% of total
lymphocytes). This patient had no history of major infections
and had a sole autoimmune manifestation of pernicious anemia.
She is currently on Ig replacement therapy with no inflammatory
lung complications.
The B cell count may be preserved because of the
lymphoproliferation (17). Kuijpers et al. (6) found a disturbed
B cell population distribution in a RAG deficient patient with
CD4+ T cell lymphopenia; an extensive antigen-independent
proliferation of the transitional, naïve and non-switched B
cells apparently accounted for the normal B cell count in
peripheral blood. Our patient shows similar phenomena in B cell
developmental abnormalities.
Expansion of gamma-delta T lymphocytes driven by severe
herpes family viral infection have been described in LS patients
with RAG variants (18, 19). Interestingly, we noticed that our
patient presented a marked increase in both B cell and CD8+
T cells counts and a lesser increase in CD4+ T cells during
herpes family virus asymptomatic viremia (CMV and EBV) and
stomatitis (HSV) (Table 1, Figure 1). The reduction of EBV
and CMV copies in peripheral blood and the resolution of the
stomatitis were followed by a reduction in B and T cell counts.
Late onset progressive hypogammaglobulinemia is less
common in combined immunodeficiencies that present early in
life with profound antibody deficiency. However, key feature of
late onset progressive hypogammaglobulinemia occurs among
patients with IKAROS deficiency (20). Large studies have not
been published on naïve IgG levels of RAG deficient patients
in different age groups as most published patients receive
Ig replacement therapy early in life. Therefore, it is yet to
be determined how large is the subgroup with late onset
progressive hypogammaglobulinemia.
Indication of hematopoietic stem cell transplantation (HSCT)
are unclear for late onset CID and RAG deficiency. The patient
is clinically well on Ig replacement therapy. There is still
concern for progressive inflammatory lung disease, or occurrence
of autoimmune complication, as reported by our group (10).
Only a selected number of adolescent and adults with partial
RAG deficiency received HSCT with variable success (21, 22).
Allogeneic HSCT is a viable option for our patient; we are
discussing with the family whether it is worthwhile given the
patient’s good response to current treatment vs. the risk of
potential inflammatory and/or autoimmune sequela. With recent
advances in gene therapy, our patient may be a candidate for this
approach as well. The compound heterozygous variant, however,
may create another layer of complexity in this process.
In conclusion, we found a novel compound heterozygous
RAG2 variants that results in 16% relative recombinase activity
and CID phenotype with normal B cell count but skewed
B cells subsets and late-onset hypogammaglobulinemia. RAG
deficiency may present with many different phenotypes and
should be considered in patients with early-onset infections.
This is especially true with T cell lymphopenia and low
naïve T cell counts, even with normal B cell counts and
late-onset hypogammaglobulinemia as in our case study. The
immune phenotype can be modified by herpes viral infection
including skewed B cell expansion and generation of anti-
cytokine antibodies in temporal association of chronic herpes
viral infections as seen in our case and previous reports (4, 17).
Ig levels can decrease with time and should be monitored for
early intervention with Ig therapy. Identifying the underlying
genetic defect can greatly facilitate diagnosis of new phenotypes
and enable effective therapy, including HSCT.
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